Stimulation of tumor-specific immunity using tumor cell plasma membrane antigen

被引:12
|
作者
Mescher, MF [1 ]
Savelieva, E [1 ]
机构
[1] UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455
来源
关键词
D O I
10.1006/meth.1997.0466
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Plasma membranes isolated from tumor cells retain biologically active class I MHC proteins on their surfaces. CD8(+) T-cell activation by membrane antigen is much more effective when the small membrane vesicles (<1-mu m diameter) are displayed on a surface with dimensions approaching those of a cell (5-mu m diameter). Previous work had shown that tumor membrane antigen incorporated onto silica microspheres could augment tumor-specific CTL responses in vivo and significantly reduce syngeneic tumor growth. Antigen on cell-sized solid supports has been termed large multivalent immunogen (LMI). Methods are described for preparing LMI using either silica or latex microspheres. LMI made using either ave active in vivo in reducing tumor growth, suggesting that the nature of the support is not critical as long as it is of the appropriate dimensions and has a surface that allows adsorption of the membrane vesicles. Latex microspheres provide some advantages over the previously described silica microspheres with respect to handling and characterization. The effects of LMI on in vivo CTL activation and tumor growth suggest that this approach may have potential for application to clinical immunotherapy of cancers. (C) 1997 Academic Press.
引用
收藏
页码:155 / 164
页数:10
相关论文
共 50 条
  • [31] Priming or tolerization of tumor-specific T cell immunity; Lessons from murine tumor models
    Offringa, R
    Toes, REM
    Schoenberger, SP
    Melief, CJM
    SPECIFIC IMMUNOTHERAPY OF CHRONIC AUTOIMMUNE DISEASES: HOW TO TRANSLATE THE EXPERIENCE OF THE EXPERIMENTAL MODELS INTO NOVEL TREATMENT MODALITIES, 1999, : 41 - 49
  • [32] A TUMOR-SPECIFIC MEMBRANE PHOSPHOPROTEIN MARKER IN HUMAN CELL HYBRIDS
    DER, CJ
    STANBRIDGE, EJ
    CELL, 1981, 26 (03) : 429 - 438
  • [33] GENERAL AND TUMOR-SPECIFIC CELL-MEDIATED-IMMUNITY IN MICE BEARING LEWIS LUNG TUMOR
    KURATA, T
    ELBLING, L
    MICKSCHE, M
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1977, 6 (6-7) : 718 - 718
  • [34] TUMOR-SPECIFIC IMMUNITY ASSAYED IN-VITRO BY CELL GROWTH INHIBITION
    JAGARLAMOODY, S
    AUST, JC
    TEW, RH
    MCKHANN, CF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1970, 11 : 40 - +
  • [35] Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine
    Tadashi Kumamoto
    Eric K. Huang
    Hyun Joon Paek
    Akimichi Morita
    Hiroyuki Matsue
    Robert F. Valentini
    Akira Takashima
    Nature Biotechnology, 2002, 20 : 64 - 69
  • [36] Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine
    Kumamoto, T
    Huang, EK
    Paek, HJ
    Morita, A
    Matsue, H
    Valentini, RF
    Takashima, A
    NATURE BIOTECHNOLOGY, 2002, 20 (01) : 64 - 69
  • [37] Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine
    Kumamoto, T
    Huang, E
    Valentini, R
    Takashima, A
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 450 - 450
  • [38] FATE OF CIRCULATING METHYLCHOLANTHRENE TUMOR CELLS IN MICE WITH TUMOR-SPECIFIC IMMUNITY
    WEXLER, H
    CHREITIE.PB
    KETCHAM, AS
    CANCER, 1971, 28 (03) : 641 - &
  • [39] DISTINCTION OF ALLOGENEIC IMMUNITY FROM TUMOR-SPECIFIC IMMUNITY IN MAN
    PARKS, LC
    SMITH, WJ
    WILLIAMS, GM
    SURGERY, 1974, 76 (01) : 43 - 49
  • [40] PURIFICATION OF A SOLUBLE TUMOR-SPECIFIC TRANSPLANTATION ANTIGEN
    PELLIS, N
    SHULAN, D
    KAHAN, B
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 11 - 11